Currently, there are no established guidelines regarding qualification for CPM; however, it is recommended that the procedure be “dissuaded” in women at an average risk of contralateral breast cancer and considered in all women at the highest risk of contralateral breast cancer, including women with a BRCA1 or BRCA2 mutation. The gene discussed is BRCA2; the disease is breast carcinoma.